시장보고서 | 연간정보서비스 | 맞춤형시장조사 | 메일링 | 샘플 요청 목록
세계의 안구 염증 치료 시장 보고서(2025년)
Ocular Inflammation Treatment Global Market Report 2025
상품코드 : 1825839
리서치사 : The Business Research Company
발행일 : On Demand Report
페이지 정보 : 영문 250 Pages
 라이선스 & 가격 (부가세 별도)
US $ 4,490 ￦ 6,625,000
PDF (Single User License) help
PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 6,490 ￦ 9,576,000
PDF (Site License) help
PDF 보고서를 동일 사업장의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 8,490 ￦ 12,527,000
PDF (Enterprise License) help
PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.


ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.

한글목차

안구 염증 치료 시장 규모는 향후 몇 년 동안 강력한 성장이 예상됩니다. 2029년 연평균 성장률(CAGR)은 5.2%로 120억 8,000만 달러에 달할 것으로 예상됩니다. 예측 기간 동안의 성장은 생물학적 제제 및 표적 치료제에 대한 수요 증가, 조기 진단 및 개입에 대한 중요성, 의료비 지출 증가, 안과 의료에 대한 접근성 확대, 원격 안과 솔루션의 채택 확대, 새로운 치료에 대한 규제 지원 등에 기인하는 것으로 보입니다. 예측 기간의 주요 동향으로는 생물학적 치료로의 전환, 약물전달의 발전, 맞춤형 의료 접근, 원격 안과 의료와의 통합, 안전성과 유효성에 대한 규제 강화, 치료 옵션의 확대 등을 꼽을 수 있습니다.

향후 5년간 5.2%의 성장률 전망은 지난번 예측보다 0.8% 소폭 하락한 수치입니다. 이 감소는 주로 미국과 다른 국가 간의 관세의 영향에 기인합니다. 관세 장벽은 아일랜드와 인도에서 조달하는 부신피질 스테로이드제 유리체강내주사제 및 면역억제제 점안제 비용을 상승시키고, 포도막염 치료를 지연시키고, 안과 진료비를 상승시킴으로써 미국을 저해할 것으로 예상됩니다. 또한, 상호 관세와 무역 긴장과 제한의 증가로 인한 세계 경제와 무역에 대한 악영향으로 인해 그 영향은 더욱 광범위하게 나타날 것으로 보입니다.

고령자 비율의 증가는 안구 염증 치료 시장의 성장을 촉진할 것으로 예상됩니다. 노화는 점진적인 생리적 쇠퇴와 조직의 완전성 상실을 특징으로 하는 자연스러운 과정이지만, 의료 서비스의 개선, 출산율 감소, 평균 수명 연장 등의 요인으로 인해 증가 추세에 있습니다. 고령화 사회가 확대됨에 따라 노화에 따른 염증 관련 증상으로부터 시력을 관리하고 보호하는 안구 염증 치료의 수요가 증가하고 있습니다. 예를 들어, 세계보건기구(WHO) 보고서에 따르면 60세 이상 인구는 2020년 10억 명에서 2022년 14억 명으로 크게 증가하고, 2030년에는 전 세계 인구 6명 중 1명이 60세 이상이 될 것으로 예측하고 있습니다. 그 결과, 고령화 인구의 증가는 안구 염증 치료 시장을 견인할 것입니다.

목차

제1장 주요 요약

제2장 시장 특징

제3장 시장 동향과 전략

제4장 시장 : 금리, 인플레이션, 지정학, 무역 전쟁과 관세, 그리고 코로나와 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오

제5장 세계의 성장 분석과 전략 분석 프레임워크

제6장 시장 세분화

제7장 지역별·국가별 분석

제8장 아시아태평양 시장

제9장 중국 시장

제10장 인도 시장

제11장 일본 시장

제12장 호주 시장

제13장 인도네시아 시장

제14장 한국 시장

제15장 서유럽 시장

제16장 영국 시장

제17장 독일 시장

제18장 프랑스 시장

제19장 이탈리아 시장

제20장 스페인 시장

제21장 동유럽 시장

제22장 러시아 시장

제23장 북미 시장

제24장 미국 시장

제25장 캐나다 시장

제26장 남미 시장

제27장 브라질 시장

제28장 중동 시장

제29장 아프리카 시장

제30장 경쟁 구도와 기업 개요

제31장 기타 주요 기업과 혁신적 기업

제32장 세계의 시장 경쟁 벤치마킹과 대시보드

제33장 주요 인수합병

제34장 최근의 시장 동향

제35장 시장 잠재력이 높은 국가, 부문, 전략

제36장 부록

KSM
영문 목차

영문목차

Ocular inflammation treatment involves medical interventions aimed at reducing swelling and safeguarding the eyes from damage caused by inflammation, ensuring clear vision and eye health. Typically, treatment for ocular inflammation encompasses medication, eye drops, and occasionally additional therapies, tailored to the severity and underlying cause of the inflammation.

The primary types of ocular inflammation treatment include immunosuppressants, antivirals, corticosteroids, antibiotics, analgesics, monoclonal antibodies, antifungals, and cycloplegics. Immunosuppressants are medications designed to diminish the activity of the body's immune system, thereby aiding in controlling inflammation in the eyes. These treatment modalities are administered via injectables, orals, topicals, and other routes, targeting disease types such as anterior uveitis, intermediate uveitis, episcleritis/scleritis, posterior uveitis, and panuveitis. The distribution channels for these treatment products include retail pharmacies, online pharmacies, hospital pharmacies, and drug stores.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sharp rise in U.S. tariffs and the resulting trade tensions in spring 2025 are having a significant impact on the healthcare sector, especially in the supply of essential medical devices, diagnostic equipment, and pharmaceuticals. Hospitals and healthcare providers are grappling with higher costs for imported surgical tools, imaging systems, and consumables like syringes and catheters, many of which have limited domestic substitutes. These escalating expenses are putting pressure on healthcare budgets, prompting some providers to delay equipment upgrades or pass increased costs on to patients. Furthermore, tariffs on raw materials and components are disrupting the manufacturing of vital drugs and devices, leading to supply chain delays. In response, the industry is adopting diversified sourcing strategies, expanding local production where feasible, and pushing for tariff exemptions on critical medical products.

The ocular inflammation treatment market research report is one of a series of new reports from The Business Research Company that provides ocular inflammation treatment market statistics, including ocular inflammation treatment industry global market size, regional shares, competitors with a ocular inflammation treatment market share, detailed ocular inflammation treatment market segments, market trends and opportunities, and any further data you may need to thrive in the ocular inflammation treatment industry. This ocular inflammation treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The ocular inflammation treatment market size has grown strongly in recent years. It will grow from $9.38 billion in 2024 to $9.86 billion in 2025 at a compound annual growth rate (CAGR) of 5.1%. The growth in the historic period can be attributed to advancements in ophthalmic research, an increased incidence of ocular inflammatory conditions, a growing aging population, the expansion of healthcare infrastructure, rising awareness about eye health, innovation in treatment modalities, and the and the development of novel therapeutics.

The ocular inflammation treatment market size is expected to see strong growth in the next few years. It will grow to $12.08 billion in 2029 at a compound annual growth rate (CAGR) of 5.2%. The growth in the forecast period can be attributed to rising demand for biologics and targeted therapies, emphasis on early diagnosis and intervention, increasing healthcare expenditure, expanding access to ophthalmic care, growing adoption of teleophthalmology solutions, regulatory support for novel treatments. Major trends in the forecast period include shift towards biologic therapies, advancements in drug delivery, personalized medicine approaches, teleophthalmology integration, regulatory emphasis on safety and efficacy, expansion of therapeutic options.

The forecast of 5.2% growth over the next five years reflects a modest reduction of 0.8% from the previous estimate for this market. This reduction is primarily due to the impact of tariffs between the US and other countries. Tariff barriers are expected to hamper the U.S. by increasing the cost of corticosteroid intravitreal implants and immunosuppressive eye drops sourced from Ireland and India, thereby delaying treatment for uveitis and elevating ophthalmology clinic expenditures. The effect will also be felt more widely due to reciprocal tariffs and the negative effect on the global economy and trade due to increased trade tensions and restrictions.

The increasing proportion of elderly individuals is anticipated to stimulate growth in the ocular inflammation treatment market. Aging, a natural process characterized by gradual physiological decline and tissue integrity loss, is on the rise due to factors such as improved healthcare, declining birth rates, and increased life expectancy. As the aging population expands, the demand for ocular inflammation treatment rises to manage and safeguard vision against age-related inflammation-related conditions. For instance, a report from the World Health Organization projected a significant increase in the demographic of individuals aged 60 and above, from 1 billion in 2020 to 1.4 billion by 2022, with estimates suggesting that one out of every six individuals globally will be aged 60 or older by 2030. Consequently, the aging population's growth will propel the ocular inflammation treatment market.

Prominent players in the ocular inflammation treatment sector are concentrating on integrating advanced technologies, such as self-emulsifying drug delivery system (SEDDS) technology, into eye drops. This integration aims to enhance drug absorption, extend therapeutic effects, and improve patient convenience. SEDDS technology in eye drops enhances bioavailability and ocular absorption of therapeutic agents, promising more effective treatment outcomes for various ocular conditions. For example, ENTOD Pharmaceuticals launched CYCLOTEARS eye drops in May 2023, targeting patients with inflammatory dry eye disease, a prevalent condition. CYCLOTEARS stands out as the world's first dry eye therapy to feature the company's proprietary SEDDS technology, developed by Indian scientists endorsed by the Department of Scientific and Industrial Research (DSIR). Collaborations with esteemed eye research institutes across India have been instrumental in the technology's development.

In June 2023, Bausch + Lomb acquired eye care products from Novartis AG for $1.75 billion, strategically strengthening its presence in the dry eye disease market segment. This acquisition, featuring Xiidra as a key asset, enhances Bausch + Lomb's ability to address the prevalent condition affecting millions globally. Novartis AG, a Swiss pharmaceutical corporation, specializes in producing drugs for ocular inflammation treatment.

Major companies operating in the ocular inflammation treatment market are Pfizer Inc., Johnson & Johnson Services Inc., F. Hoffmann-La Roche Ltd., Merck & Co. Inc., AbbVie Inc., Novartis AG, GlaxoSmithKline plc, Amgen Inc., Teva Pharmaceutical Industries Ltd., Regeneron Pharmaceuticals Inc., Mylan N.V., Bristol Myers Squibb Company, Alcon Laboratories Inc., Bausch Health Companies Inc., Macleods Pharmaceuticals Ltd, Intas Pharmaceuticals Ltd, Cipla Inc., Santen Pharmaceutical Co. Ltd., Mallinckrodt Pharmaceuticals, Akron Pharma Inc, Sun Pharmaceutical Industries Ltd., Alimera Sciences, Ocular Therapeutix Inc., EyePoint Pharmaceuticals Inc., Tarsier Pharma, Graybug Vision Inc., EyeGate, Oculis S.A.

North America was the largest region in the ocular inflammation treatment market in 2024. The regions covered in the ocular inflammation treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the ocular inflammation treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The ocular inflammation treatment market consists of revenues earned by entities by providing services such as diagnostic services, treatment administration services, patient support programs, telemedicine, and remote monitoring services. The market value includes the value of related goods sold by the service provider or included within the service offering. The ocular inflammation treatment market also includes sales of long-acting corticosteroid implants, contact lenses, compounded medications, and biodegradable inserts. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Ocular Inflammation Treatment Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on ocular inflammation treatment market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Where is the largest and fastest growing market for ocular inflammation treatment ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The ocular inflammation treatment market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.

Scope

Table of Contents

1. Executive Summary

2. Ocular Inflammation Treatment Market Characteristics

3. Ocular Inflammation Treatment Market Trends And Strategies

4. Ocular Inflammation Treatment Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

5. Global Ocular Inflammation Treatment Growth Analysis And Strategic Analysis Framework

6. Ocular Inflammation Treatment Market Segmentation

7. Ocular Inflammation Treatment Market Regional And Country Analysis

8. Asia-Pacific Ocular Inflammation Treatment Market

9. China Ocular Inflammation Treatment Market

10. India Ocular Inflammation Treatment Market

11. Japan Ocular Inflammation Treatment Market

12. Australia Ocular Inflammation Treatment Market

13. Indonesia Ocular Inflammation Treatment Market

14. South Korea Ocular Inflammation Treatment Market

15. Western Europe Ocular Inflammation Treatment Market

16. UK Ocular Inflammation Treatment Market

17. Germany Ocular Inflammation Treatment Market

18. France Ocular Inflammation Treatment Market

19. Italy Ocular Inflammation Treatment Market

20. Spain Ocular Inflammation Treatment Market

21. Eastern Europe Ocular Inflammation Treatment Market

22. Russia Ocular Inflammation Treatment Market

23. North America Ocular Inflammation Treatment Market

24. USA Ocular Inflammation Treatment Market

25. Canada Ocular Inflammation Treatment Market

26. South America Ocular Inflammation Treatment Market

27. Brazil Ocular Inflammation Treatment Market

28. Middle East Ocular Inflammation Treatment Market

29. Africa Ocular Inflammation Treatment Market

30. Ocular Inflammation Treatment Market Competitive Landscape And Company Profiles

31. Ocular Inflammation Treatment Market Other Major And Innovative Companies

32. Global Ocular Inflammation Treatment Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Ocular Inflammation Treatment Market

34. Recent Developments In The Ocular Inflammation Treatment Market

35. Ocular Inflammation Treatment Market High Potential Countries, Segments and Strategies

36. Appendix

(주)글로벌인포메이션 02-2025-2992 kr-info@giikorea.co.kr
ⓒ Copyright Global Information, Inc. All rights reserved.
PC버전 보기